AIA Group Ltd Purchases 365 Shares of Moderna, Inc. (NASDAQ:MRNA)

AIA Group Ltd boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,264 shares of the company’s stock after acquiring an additional 365 shares during the quarter. AIA Group Ltd’s holdings in Moderna were worth $1,419,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ICA Group Wealth Management LLC bought a new position in shares of Moderna in the fourth quarter valued at about $27,000. First Pacific Financial bought a new position in shares of Moderna in the third quarter valued at about $27,000. Stonebridge Capital Advisors LLC grew its stake in shares of Moderna by 79.1% in the first quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock valued at $49,000 after acquiring an additional 125 shares in the last quarter. Arlington Trust Co LLC grew its stake in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its stake in shares of Moderna by 173.5% in the first quarter. Parkside Financial Bank & Trust now owns 309 shares of the company’s stock valued at $53,000 after acquiring an additional 196 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on MRNA shares. Canaccord Genuity Group upped their price target on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research note on Friday, February 23rd. HSBC restated a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 price target on shares of Moderna in a research note on Thursday, March 28th. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Finally, William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $126.49.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares in the company, valued at approximately $406,651. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the completion of the sale, the president now owns 1,486,241 shares of the company’s stock, valued at approximately $156,085,029.82. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at approximately $406,651. The disclosure for this sale can be found here. Insiders sold a total of 94,954 shares of company stock worth $9,983,276 in the last quarter. 15.70% of the stock is owned by insiders.

Moderna Price Performance

MRNA opened at $102.85 on Friday. The company’s 50 day moving average is $100.35 and its 200-day moving average is $93.65. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $144.43. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm’s quarterly revenue was down 44.9% on a year-over-year basis. During the same quarter last year, the business earned $3.61 EPS. As a group, equities analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.